- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04535245
Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD
March 22, 2023 updated by: Richard Meehan, National Jewish Health
Lung Clearance Measurement to Determine Pre-clinical Airway Involvement in Scleroderma Patients Without Lung Disease as a Risk Factor for Developing ILD
This National Jewish Health (NJH) Investigator Initiated pilot study funded by the Shah Foundation will prospectively perform a non invasive lung function test called Lung Clearance Index (LCI) to determine if 50 scleroderma patients without evidence of lung disease who have evidence of small airway inflammation or impairment to airflow are more likely to develop ILD than those with normal vales.50
subjects will be enrolled from the Rheumatology practice at NJH and followed with phone interviews or Electronic Medical Record (EMR) record review yearly times 5 to determine if they have subsequently developed evidence of ILD or pulmonary artery hypertension.
Study Overview
Detailed Description
50 scleroderma patients without evidence of lung disease who have been seen by an NJH Rheumatologist will be invited to participate.
They will have their medical records reviewed to determine eligibility and then perform hand held spirometry and LCI testing.
This measures evidence of small airway airflow obstruction and requires normal breathing while first on room air followed by inhaling a gas mixture of 100% oxygen.
The Oxygen concentration in exhaled breathing and the number of breaths needed to return to room air concentration of Oxygen will be analyzed by a computer.
Medical information from the EMR will be recorded and placed in a secure database, REDCap, for statistical analysis to determine if LCI results or other clinical features are predictive of which Scleroderma patients are most likely to subsequently develop evidence of Interstitial Lung disease (ILD) based upon yearly phone call interviews and EMR record reviews within 5 years of baseline testing.
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Richard T meehan, MD
- Phone Number: 303 3981-1475
- Email: meehanr@njhealth.org
Study Contact Backup
- Name: Mary Gill, RN
- Phone Number: 720 936-9619
- Email: gillm@njhealth.org
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Recruiting
- National Jewish Health
-
Contact:
- Richard T Meehan, MD
- Phone Number: 303-398-1475
- Email: meehanr@njhealth.org
-
Sub-Investigator:
- Mehrnaz Maleki, MD
-
Sub-Investigator:
- Liudmila Kastsianok, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Scleroderma patients without lung disease
Description
Inclusion Criteria:
- Confirmed diagnosis of systemic sclerosis (SSC) by an NJH Rheumatologist
- age 21-75
- No evidence of Scleroderma related Lung disease (ILD)
- Able to comprehend and sign an Institutional Review Board (IRB) approved consent form.
Exclusion Criteria:
- Patients without a Rheumatologists confirming a diagnosis (DX) of SSC
- Patients with evidence of lung involvement based upon; Thoracic imaging, abnormal Pulmonary Function Tests (PFTs); Forced Vital Capacity( FVC), Forced Expiratory Volume in 1 second (FEV1) or a Diffusion Capacity for Carbon Monoxide (DLCO) < the Lower Limit of Normal (LLN) or Saturation of Oxygen in arterial blood (SaO2) < 90% .
- Cardiac echocardiogram or right heart catheter evidence of Pulmonary Arterial Hypertension (PAH).
- < 21 or > 75 years of age
- Must not be pregnant or had eye surgery within 2 weeks of LCI testing
- Must be able to comprehend and sign an IRB approved consent form and complete LCI testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
LCI testing
LCI testing will be performed on all study subjects
|
all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Utility of Lung Clearance Index Scores at predicting Interstitial Lung disease ( ILD) development within 5 years among Scleroderma patients without ILD.
Time Frame: 5 years after baseline testing
|
Lung clearance index values (LCI) will be measured from all Scleroderma patients at baseline (normal value is < 7 ).
The LCI scores from the cohort of Scleroderma patients who subsequently develop ILD based upon physician review of the EMR or phone interviews will be compared to the LCI scores from those scleroderma patients who did not develop ILD.
Statistical analysis of LCI scores between both cohorts will determine the potential clinical utility of this non-invasive measurement of lung function in identifying those scleroderma patients who are at greatest risk for the subsequent development of ILD so treatment can be initiated early in their disease before irreversible pulmonary fibrosis develops.
|
5 years after baseline testing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard T Meehan, MD, National Jewish Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 4, 2021
Primary Completion (Anticipated)
January 15, 2026
Study Completion (Anticipated)
January 15, 2026
Study Registration Dates
First Submitted
August 12, 2020
First Submitted That Met QC Criteria
August 31, 2020
First Posted (Actual)
September 1, 2020
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 22, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS 3471
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scleroderma
-
University of Texas Southwestern Medical CenterRecruitingScleroderma, Localized | Morphea | Frontal Linear Scleroderma en Coup de Sabre | Scleroderma, Circumscribed | Scleroderma, LinearUnited States
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Gilead SciencesCompletedDiffuse Scleroderma | Limited SclerodermaAustralia
-
Mastelli S.r.lSintesi Research SrlTerminatedScleroderma DiseaseItaly
-
Lawson Health Research InstituteNovartis PharmaceuticalsTerminated
-
BiocadRecruitingSystemic SclerodermaRussian Federation
-
Rennes University HospitalCompleted
-
Castle Creek Biosciences, LLC.TerminatedScleroderma, Localized | Morphea | SclerodermaUnited States
-
Assistance Publique - Hôpitaux de ParisActelionCompleted
-
University Hospital, LilleRecruiting
Clinical Trials on LCI testing
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Affiliated Hospital to Academy of Military Medical...Shanghai 10th People's Hospital; Sixth Affiliated Hospital, Sun Yat-sen University and other collaboratorsCompletedGastritis | Atrophic Gastritis | Helicobacter Pylori Associated GastritisChina
-
National Jewish HealthActive, not recruitingChronic Lung DiseaseUnited States
-
Duke UniversityNational Cancer Institute (NCI); Jacobi Medical CenterCompleted
-
Changhai HospitalGuilin Medical University, China; Shanxi Province Cancer Hospital; First People... and other collaboratorsUnknownEarly Gastric CancerChina
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
National Jewish HealthCompletedBronchiolitis | Dyspnea | PneumonitisUnited States
-
Duke UniversityNational Cancer Institute (NCI); University of North Carolina, Chapel HillCompleted
-
Johannes Gutenberg University MainzUnknownFocus of the Study is to Evaluate a New Developed Deep-learning Computer-aided Detection System in Combination With LCI for Colorectal Polyp DetectionGermany
-
University of ZurichWithdrawnLung Transplantation | Chronic Lung Allograft Dysfunction | Rejection Lung Transplant